-
Ever wondered if Sandoz Group stock could be a hidden value play, or if you're just jumping in after the most exciting moves? Let's find out what might actually be under the hood.
-
After a rocky 2.4% dip over the past week, Sandoz has surged by 10.1% in the last month and is showing off an impressive 43.6% gain year-to-date. This signals renewed interest and shifting market perceptions.
-
Much of this price action has been driven by ongoing headlines around the company's strategic investments in innovative generics and biosimilars, as well as updates on sector partnerships. If you caught recent coverage, you know the buzz is more about long-term growth ambitions than short-term profitability.
-
On our valuation scorecard, Sandoz Group clocks in at 2 out of 6 for undervalued checks. This means there is plenty left to analyze, so let's dig into how we measure value, and circle back at the end for a smarter way to put it all together.
Sandoz Group scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown .
Approach 1: Sandoz Group Discounted Cash Flow (DCF) Analysis
The Discounted Cash Flow (DCF) model is a common way to estimate what a company is truly worth by projecting its future cash flows and then discounting those flows back to today's value. This approach focuses on how much money the business is expected to generate over time, making it a key tool for gauging underlying value beyond short-term market moves.
For Sandoz Group, the latest reported annual Free Cash Flow stands at $332.1 Million. According to analysts, Sandoz's Free Cash Flow is projected to rise steadily, crossing the $1.1 Billion mark by 2026 and reaching nearly $1.5 Billion by 2029. Further out, extrapolated estimates continue this upward trend for the next five years.
Based on these long-term projections, the DCF analysis assigns Sandoz an intrinsic value of $88.39 per share. With the current share price trading at a 39.0% discount to this value, the model indicates the stock is significantly undervalued at present.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Sandoz Group is undervalued by 39.0%. Track this in your watchlist or portfolio , or discover 898 more undervalued stocks based on cash flows .
Approach 2: Sandoz Group Price vs Earnings
For companies that are earning steady profits, the Price-to-Earnings (PE) ratio is the go-to metric for quick valuation checks. The PE ratio tells you how much investors are willing to pay for each dollar of current earnings, making it especially relevant for understanding how the market values near-term business performance.
However, what counts as a "normal" or "fair" PE ratio is not set in stone. It typically depends on expectations for future growth and the level of risk. Companies with higher growth prospects or lower risk profiles usually deserve a higher PE, while mature or riskier companies see lower multiples.
Currently, Sandoz Group trades at a PE ratio of 127.1x, which stands well above the Pharmaceuticals industry average of 23.8x and higher than its peer group average of 50.3x. On the surface, this suggests investors are paying a major premium for Sandoz compared to both the overall industry and similar companies.
But straight comparisons can be misleading. This is where the Simply Wall St Fair Ratio comes in, which estimates a "just right" multiple (32.8x in this case) tailored to Sandoz specifically. This proprietary benchmark takes into account the company's future growth, profit margin, risks, industry grouping, and overall size, giving a far more nuanced benchmark than broad averages.
When you stack Sandoz's actual PE of 127.1x against its Fair Ratio of 32.8x, it is clear the stock is richly valued on this measure. This may be a sign that investors are baking in ambitious expectations or that the recent surge may have gotten ahead of fundamentals.
Result: OVERVALUED
PE ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1416 companies where insiders are betting big on explosive growth .
Upgrade Your Decision Making: Choose your Sandoz Group Narrative
Earlier we mentioned that there is an even better way to understand valuation, so let's introduce you to Narratives. Narratives are a smarter, more dynamic approach that ties together the story you believe about a company with its financial forecasts, letting you map your perspective directly to its fair value. Instead of just relying on standard models, Narratives invite you to outline your assumptions, such as future revenue, earnings, and profit margins, so your valuation is built around your view of Sandoz Group's business and outlook, not just raw numbers.
This tool, which millions of investors use on the Simply Wall St platform's Community page, makes it easy to compare what you think the company is worth with what the market is currently pricing in. When new news or earnings are released, Narratives update automatically, so your fair value moves with the latest information, helping you decide when to buy, hold, or sell with real confidence.
For example, some Sandoz Group Narratives assume rapid pipeline expansion and sustainable margin growth, leading to bullish price targets as high as CHF60.37. Others cite pricing pressures or regulatory risks and value the stock as low as CHF38.02, showing how your belief about the company's story can translate into very different investment decisions.
Do you think there's more to the story for Sandoz Group? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SDZ.SW .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
